Switch theme
Sign up to access all valuation multiples
Synektik SA is a supplier of innovative products, services and IT solutions for diagnostic imaging and nuclear medicine. It sells medical devices and IT solutions used in radiology and operates research laboratory for diagnostic imaging systems and a service centre for medical equipment. Its operating segments include the sale of medical equipment used in radiology and nuclear medicine and IT solutions, Maintenance services for medical equipment as well as acceptance and specialist tests and Radiopharmaceutical production.
2011
n/a
LTM Revenue $210M
LTM EBITDA $51.5M
$499M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Synektik has a last 12-month revenue (LTM) of $210M and a last 12-month EBITDA of $51.5M.
In the most recent fiscal year, Synektik achieved revenue of $173M and an EBITDA of $33.7M.
Synektik expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Synektik valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $210M | XXX | $173M | XXX | XXX | XXX |
| Gross Profit | $94.6M | XXX | $52.5M | XXX | XXX | XXX |
| Gross Margin | 45% | XXX | 30% | XXX | XXX | XXX |
| EBITDA | $51.5M | XXX | $33.7M | XXX | XXX | XXX |
| EBITDA Margin | 25% | XXX | 20% | XXX | XXX | XXX |
| EBIT | $42.5M | XXX | $30.0M | XXX | XXX | XXX |
| EBIT Margin | 20% | XXX | 17% | XXX | XXX | XXX |
| Net Profit | $33.5M | XXX | $22.8M | XXX | XXX | XXX |
| Net Margin | 16% | XXX | 13% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 31, 2025, Synektik's stock price is PLN 214 (or $59).
Synektik has current market cap of PLN 1.8B (or $505M), and EV of PLN 1.8B (or $499M).
See Synektik trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $499M | $505M | XXX | XXX | XXX | XXX | $4.58 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 31, 2025, Synektik has market cap of $505M and EV of $499M.
Synektik's trades at 2.7x EV/Revenue multiple, and 12.8x EV/EBITDA.
Equity research analysts estimate Synektik's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Synektik has a P/E ratio of 15.1x.
See valuation multiples for Synektik and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $505M | XXX | $505M | XXX | XXX | XXX |
| EV (current) | $499M | XXX | $499M | XXX | XXX | XXX |
| EV/Revenue | 2.4x | XXX | 2.7x | XXX | XXX | XXX |
| EV/EBITDA | 9.7x | XXX | 12.8x | XXX | XXX | XXX |
| EV/EBIT | 11.8x | XXX | 14.8x | XXX | XXX | XXX |
| EV/Gross Profit | 5.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | 15.1x | XXX | 19.4x | XXX | XXX | XXX |
| EV/FCF | 32.9x | XXX | 23.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialSynektik's last 12 month revenue growth is 19%
Synektik's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Synektik's rule of 40 is 38% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Synektik's rule of X is 73% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Synektik and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 19% | XXX | 17% | XXX | XXX | XXX |
| EBITDA Margin | 25% | XXX | 21% | XXX | XXX | XXX |
| EBITDA Growth | 25% | XXX | 50% | XXX | XXX | XXX |
| Rule of 40 | 38% | XXX | 40% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 73% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 7% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 4% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 13% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Synektik acquired XXX companies to date.
Last acquisition by Synektik was XXXXXXXX, XXXXX XXXXX XXXXXX . Synektik acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Synektik founded? | Synektik was founded in 2011. |
| Where is Synektik headquartered? | Synektik is headquartered in Poland. |
| Is Synektik publicy listed? | Yes, Synektik is a public company listed on WAR. |
| What is the stock symbol of Synektik? | Synektik trades under SNT ticker. |
| When did Synektik go public? | Synektik went public in 2011. |
| Who are competitors of Synektik? | Similar companies to Synektik include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Synektik? | Synektik's current market cap is $505M |
| What is the current revenue of Synektik? | Synektik's last 12 months revenue is $210M. |
| What is the current revenue growth of Synektik? | Synektik revenue growth (NTM/LTM) is 19%. |
| What is the current EV/Revenue multiple of Synektik? | Current revenue multiple of Synektik is 2.4x. |
| Is Synektik profitable? | Yes, Synektik is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Synektik? | Synektik's last 12 months EBITDA is $51.5M. |
| What is Synektik's EBITDA margin? | Synektik's last 12 months EBITDA margin is 25%. |
| What is the current EV/EBITDA multiple of Synektik? | Current EBITDA multiple of Synektik is 9.7x. |
| What is the current FCF of Synektik? | Synektik's last 12 months FCF is $15.2M. |
| What is Synektik's FCF margin? | Synektik's last 12 months FCF margin is 7%. |
| What is the current EV/FCF multiple of Synektik? | Current FCF multiple of Synektik is 32.9x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
